VV

Vivos Therapeutics IncNASDAQ VVOS Stock Report

Last reporting period 30 Jun, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.01

Micro

Exchange

XNAS - Nasdaq

VVOS Stock Analysis

VV

Uncovered

Vivos Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

7/100

Low score

Market cap $B

0.01

Dividend yield

Shares outstanding

25.012 B

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Littleton, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization of diagnostic and treatment modalities for patients with dentofacial abnormalities and/or patients with mild to moderate obstructive sleep apnea (OSA) and snoring in adults. The firm call its OSA treatment protocol as The Vivos Method. The Vivos Method is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities and/or mild to moderate OSA and snoring. The Company’s program is to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice program. Its primary product is used in the Vivos System is the Mandibular Repositioning Nighttime Appliance (mRNA) appliance, a specifically designed, custom oral appliance.

View Section: Eyestock Rating